LENSᵃⁱ Update: IPA’s BioStrand LENSᵃⁱ™ integrates advanced HYFT™ technology to enhance LLMs and accelerate antibody discovery.
Dr. Dirk Van Hyfte, Head of Innovation and Co-Founder at BioStrand, stated, “The integration of HYFT technology into our LLMs marks a transformative moment in biotechnology."See full announcement
Register for IPA Updates
By clicking submit below, you agree that IPA may store and process your personal information to send you email updates. You can find further information in our Privacy Policy.
